|
Jul 29
|
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
|
|
Jul 24
|
European Value Stocks That Could Be Trading Below Their Estimated Worth In July 2025
|
|
May 22
|
European Stock Picks That May Be Undervalued In May 2025
|
|
Apr 17
|
3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%
|
|
Apr 16
|
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
|